Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Gvs Earnings Release 2025

Aug 7, 2025

4164_rns_2025-08-07_6c0ad5fe-3f9d-48e9-b468-ee73b3447bc9.pdf

Earnings Release

Open in viewer

Opens in your device viewer

Informazione
Regolamentata n.
2251-52-2025
Data/Ora Inizio Diffusione
7 Agosto 2025 14:14:48
Euronext Milan
Societa' : GVS
Identificativo Informazione
Regolamentata
: 209066
Utenza - referente : GVSN03 - Bala Rozemaria
Tipologia : 1.2
Data/Ora Ricezione : 7 Agosto 2025 14:14:48
Data/Ora Inizio Diffusione : 7 Agosto 2025 14:14:48
Oggetto : GVS: First Half 2025 Consolidated Results
Approval
Testo
del
comunicato

Vedi allegato

GVS CONFIRMS ITS LEADERSHIP IN PROFITABILITY, POSTING THE STRONGEST QUARTERLY PERFORMANCE SINCE Q4 2021

GVS H1 2025 Results Highlights

Consolidated revenues up 1.7% at constant exchange rates to 215.6 million euro

Healthcare & Life Sciences division revenues up +2.2% at constant exchange rates compared to H1 2024

Safety division revenues up 8.6% year-on-year at constant exchange rates in the first six months, accelerating versus Q1 2025 performance

Adjusted EBITDA up 4.1% to 54.2 million euro, with a margin for the first half at 25.1%, up 90 basis points year-on-year

Adjusted EBITDA margin for Q2 2025 at 26.2%, +120 basis points vs. Q2 2024, marking the highest profitability since Q4 2021

Adjusted net profit, excluding foreign exchange gains and losses, up 16.2% yearon-year to 26.2 million euro, improving the margin from 10.5% of H1 2024 to 12.1%

Net financial debt at 268.0 million euro, with a post-M&A leverage ratio of 2.4x

***

Zola Predosa (BO), 7 August 2025 – The Board of Directors of GVS S.p.A. (the "Company" or the "Group"), a leading provider of advanced filtration solutions for highly critical applications, met today in Zola Predosa (BO) and approved the consolidated half year report at 30 June 2025, which have been prepared in accordance with IFRS international accounting standards.

ANALYSIS OF THE GROUP'S ECONOMIC PERFORMANCE

In the first half of 2025, GVS reported consolidated revenues of 215.6 million euro, up 1.7% year-onyear at constant exchange rates and 0.4% at current exchange rates.

The Healthcare & Life Sciences division, accounting for 67.8% of total revenues, recorded sales of 146.2 million euro, representing an increase of 2.2% at constant exchange rates (+1.0% at current exchange rates) compared to the first six months of 2024, mainly driven by the acquisition of Haemonetics' whole blood business.

The Safety division, representing 18.7% of total revenues, reached 40.3 million euro, up 8.6% at constant exchange rates (+7.0% at current exchange rates) compared to the same period of the previous year, showing an acceleration versus the growth recorded in the first quarter.

The Mobility division, accounting for 13.5% of total revenues, posted sales of 29.2 million euro, down 8.5% at constant exchange rates (-10.3% at current exchange rates) compared to the same period in 2024. The division's performance was impacted by a slowdown in the automotive sector.

Adjusted EBITDA increased by 4.1% compared to the first six months of 2024 to 54,2 million euro, with a revenue margin of 25.1%, a significant improvement over the 24.2% margin recorded in the same period of the previous year. In the second quarter of 2025, the adjusted EBITDA margin reached 26.2%, up 120 basis points compared to the same quarter of 2024, marking the highest quarterly profitability level since Q4 2021.

Adjusted EBIT amounted to 39.5 million euro, up 4.9% from 37.7 million euro in the same period of the previous year, with a margin on revenues of 18.3%, in line with the growth achieved at the adjusted EBITDA level.

Adjusted net financial expenses - net of FX losses of 22.2 million euro in H1 2025 and FX gains of 3.0 million euro in H1 2024 - decreased in the reporting period, from 7.7 million euro as of June 30, 2024, to 5.0 million euro as of June 30, 2025. This improvement was mainly due to the reduction in the nominal value of outstanding loans in accordance with their respective amortization schedules and to the contractually agreed interest rates.

Adjusted net income, excluding foreign exchange gains/losses and the related tax effects, amounted to 26.2 million euro, up 16.2% compared to the first half of the previous year.

Net financial debt as of June 30, 2025, stood at 268.0 million euro. The 48.2 million euro increase versus December 31, 2024, was primarily attributable to the acquisition of Haemonetics' whole blood business. As part of this transaction, the Group paid 40.5 million euro at closing and recognized an earn-out liability of 8.9 million euro, payable in several annual instalments by February 2028. Excluding the above-mentioned acquisition and extraordinary investments carried out during the period

amounting to 5.6 million euro, net financial debt as of June 30, 2025 decreased by 6.8 million euro compared to December 31, 2024.

BUSINESS OUTLOOK

During the first quarter of 2025, the GVS Group continued on its path of continuous improvement in economic and financial performance, focusing its strategy on:

  • the full integration, within the new Transfusion Medicine subdivision, of the whole blood business acquired from Haemonetics at the beginning of the year;
  • the continuation of industrial efficiency actions, aimed at supporting a further improvement of the Group's margins;
  • the implementation of the new organisational structure of the Healthcare & Life Sciences division, aimed at maximising the growth potential of the different markets.

With regard to the impact of the new tariffs recently introduced by the U.S. administration, the Company notes the following:

  • The impact of the new tariffs in the first half of 2025 amounted to approximately Euro 350 thousand;
  • The impact in the second half of 2025 is expected to be almost entirely offset by price increases already implemented.

Following the results achieved in the first six months of the year, the Company has updated its fullyear 2025 guidance as follows:

  • Mid-to-high single-digit growth in consolidated turnover at constant exchange rates compared to FY2024, in acceleration in the second half of the year thanks to the rampup of Whole Blood revenues;
  • an increase in the adjusted EBITDA margin of between 150 and 250 basis points compared to 2024, including the tariff impact;
  • a leverage ratio expected to be around 2.2x as of 31 December 2025, including the impact of the ongoing €20m Buyback

STATEMENT PURSUANT TO ARTICLE 154-BIS, SECOND PARAGRAPH OF THE CONSOLIDATED LAW ON FINANCIAL INTERMEDIATION (TUF)

***

The Manager responsible for preparing the company's financial reports, Emanuele Stanco, declares, pursuant to article 154-bis, second paragraph of Legislative Decree 58/98, that the accounting information contained in this press release corresponds to the results in the Company's documents, books and accounting records.

***

The consolidated half year report at 30 June 2025, approved by the Board of Directors today, will be made available to the public at the Company's registered office and can be consulted on the Company's website at www.gvs.com and on the authorised storage mechanism "eMarket Storage", managed by Teleborsa Srl.

***

CONFERENCE CALL

Financial results for H1 2025 will be presented on 7 August 2025 at 16.00 pm CET during a webinar/conference call held by the Group's Senior Management.

The event can be followed in webinar or telephone mode by registering at the link below:

CLICK HERE TO REGISTER FOR THE CONFERENCE CALL & WEBINAR

The presentation given by the Senior Management will be available before the beginning of the conference call on the authorised storage mechanism eMarket Storage, managed by Teleborsa Srl, as well as on the Company's website www.gvs.com (in the section Investor Relations/Financial Presentations).

***

This press release is available on the regulated information dissemination system eMarket SDIR, managed by Teleborsa Srl, as well as on the Company's website www.gvs.com (in the Investor/Press releases section).

***

Contacts

Investor Relations GVS S.p.A. Guido Bacchelli Head of Strategy, Corporate Development and IR [email protected]

DISCLAIMER

This press release contains forward-looking statements concerning future events and operating, economic and financial results of GVS. These forecasts have by their very nature a component of risk and uncertainty, as they depend on the occurrence of future events and developments. Actual results may deviate even significantly from those announced in relation to a multitude of external factors not necessarily under GVS's control.

Consolidated Financial Statements as at 30 June 2025

Consolidated Income Statement

(In thousands of Euro) Period of 6 months ended
30 June
2025 2024
Revenue from contracts with customers 215,595 214,822
Other revenue and income 3,684 3,901
Total revenue 219,279 218,723
Purchases and consumption of raw materials, semi-finished and finished
products
(64,568) (64,435)
Personnel costs (68,777) (69,808)
Services Cost (31,280) (29,692)
Other operating costs (3,076) (3,721)
EBITDA 51,578 51,067
Net write downs of financial assets (281) (520)
Amortisation, depreciation and write downs (22,336) (21,874)
EBIT 28,961 28,673
Financial income 758 5,026
Financial costs (28,349) (12,508)
Profit before income tax 1,370 21,191
Income taxes (348) (2,171)
Net profit 1,022 19,020
Group's share 1,024 19,016
Minority share (2) 4
Basic net result per share (in Euro) 0.01 0.11
Diluted net result per share (In Euro) 0.01 0.11

Analysis of Reclassified Income Statement

Period of 6 months ended 30 June
(In thousands of euro) 2025 of which
non-
recurring
2025
Adjusted
% 2024 of which
non
recurring
2024
Adjusted
%
Revenues from sales and services 215,595 215,595 100.0% 214,822 214,822 100.0%
Other revenues and income 3,684 370 3,314 1.5% 3,901 1,137 2,764 1.3%
Total revenue 219,279 370 218,909 101.5% 218,723 1,137 217,586 101.3%
Costs for purchase of raw materials
and change in inventories
(64,568) (64,568) -29.9% (64,435) (64,435) -30.0%
Service provisions (31,280) (422) (30,858) -14.3% (29,692) (250) (29,442) -13.7%
Other operating expenses (3,076) (524) (2,552) -1.2% (3,721) (1,232) (2,489) -1.2%
Added value 120,355 (576) 120,931 56.1% 120,875 (345) 121,220 56.4%
Labour cost (68,777) (2,003) (66,774) -31.0% (69,808) (631) (69,177) -32.2%
EBITDA 51,578 (2,579) 54,157 25.1% 51,067 (976) 52,043 24.2%
Depreciation and amortisation
Provisions and write-downs
(22,336)
(281)
(7,993) (14,343)
(281)
-6.7%
-0.1%
(21,874)
(520)
(8,034) (13,840)
(520)
-6.4%
-0.2%
EBIT 28,961 (10,572) 39,533 18.3% 28,673 (9,010) 37,683 17.5%
Financial income and expenses (27,591) (470) (27,121) -12.6% (7,482) (2,810) (4,672) -2.2%
Pre-tax result 1,370 (11,042) 12,412 5.8% 21,190 (11,820) 33,011 15.4%
Income taxes (348) 2,751 (3,099) -1.4% (2,171) 6,044 (8,215) -3.8%
Group and minorities' net profit 1,022 (8,291) 9,313 4.3% 19,020 (5,776) 24,796 11.5%

Consolidated Balance Sheet

(In thousands of Euro) At 30 June 2025 At 31 December
2024
ASSETS
Non-current assets
Intangible assets 438,594 472,940
Right of use assets 21,423 23,389
Property, plant and equipment 162,349 133,756
Deferred tax assets 839 859
Non-current financial assets 1,424 3,422
Non- current derivative financial instruments 264 1,877
Total non current assets 624,893 636,243
Current assets
Inventories 98,423 80,542
Trade receivables 61,636 55,368
Contract assets 1,625 1,561
Income tax receivables 15,866 10,768
Other current assets and receivables 15,463 11,893
Current financial assets 1 .846 30,985
Current derivative financial instruments 1,290
Cash and cash equivalents 62,032 102,991
Total current assets 258,181 294,108
TOTAL ASSETS 883,074 930,351
EQUITY AND LIABILITIES
Share capital 1,892 1,892
Reserves 425,366 415,917
Profit for the period 1,024 33,370
Group shareholders' equity 428,282 451,179
Non-controlling interests 47 52
Total equity 428,329 451,231
Non-current liabilities
Payables for the purchase of equity investments and earn-outs 8,105 8,245
Non-current borrowings 203,472 246,021
Non-current lease liabilities 11,874 14,138
Deferred tax liabilities 29,928 29,937
Employee benefit obligations 3,025 2,924
Provisions for risks and charges 5,528 6,648
Non-current derivative financial instruments 399
Total non-current liabilities 262,331 307,913
Current liabilities
Payables for the purchase of equity investments and earn-outs 7,474 19,346
Current borrowings 93,301 57,221
Current lease liabilities 7.276 8,034
Current provisions for risks and charges 725 500
Current derivative financial instruments 44 382
Trade payables 46,595 42,542
Contract liabilities 5,785 5,868
Income tax payables 6,259 10,159
Other current liabilities 24,955 27,155
Total current liabilities 192,414 171,207
TOTAL EQUITY AND LIABILITIES 883,074 930,351

IT-25917-9190.GVS1

Tel. +39 051 6176311 - Fax +39 051 6176200 - e-mail: [email protected] - www.gvs.com Cap. Soc. € 1.891.776,93 int. vers. - C.F. 03636630372 - P. Iva 00644831208 EMA DI GE8TIONE
CERTIFICATO

IATF 16049
Cert. N. 9136.0

R.E.A. 0305386/BO - Reg. Imprese 45539/BO - Mecc. BO 012048 UNI EN ISO 14001
Cert. N. 7838-E

A DI GESTIC
RTIFICATO UNI EN ISO 45001
Cert. N. 7838-l Mod 3065 rev 05

Consolidated Cash Flow Statement

Period of 6 months ended 30
(In thousands of Euro) June
2025 2024
Profit before income tax 1,370 21,191
- Adjustments:
Depreciation and amortization 22,336 21,874
Capital loss / (gain) from disposal of assets (64) (રક)
Net financial expenses 27,591 7,482
Other non-monetary movements 6,909 3,885
Cash flow from operating activities before changes in net working 58,142 54,373
capital
Changes in inventory (20,102) (2,541)
Changes in trade receivables (8,122) (7,362)
Changes in trade payables 2,893 6,118
Changes in other assets and liabilities (7,247) 2,063
Uses of employee benefit obligations and provisions for risks and (4,486) (1,344)
charges
Income tax paid (9,213) (7,199)
Net cash flow provided by / (used in) operating activities 11,865 44,108
Investments in property, plant and equipment (40,970) (15,075)
Investments in intangible assets (3,605) (4,141)
Disposal of property, plant and equipment 172 200
Investments in financial assets (169) (86,172)
Disposal of financial assets 28,271 10,000
Acquisition of company branch (net of cash acquired) (19,128) (19,000)
Net cash flow provided by / (used in) investing activities (35,429) (114,189)
Proceeds of borrowings 20,041 208
Repayment of borrowings (25,685) (50,557)
Repayment of lease liabilities (4,451) (4,593)
Finance costs paid (6,003) (8,159)
Finance income received 758 1,270
Treasury shares 97 (154)
Net cash flow provided by / (used in) financing activities (15,243) (61,984)
Total cash flow provided / (used) in the year (38,807) (132,065)
Cash and cash equivalents at the beginning of the period 102,991 191,473
Total cash flow provided / (used) in the year (38,807) (132,065)
Exchange differences from translation of cash and cash equivalents (2,152) (204)
Cash and cash equivalents at the end of the period 62,032 59,203

Cuini EN ISO 9001

IT-25917-9190.GVS1

GVS S.p.A.

Via Roma, 50 - 40069 Zola Predosa (Bologna) - Italy Tel. +39 051 6176311 - Fax +39 051 6176200 - e-mail: [email protected] - www.gvs.com EMA DI GE8TIONE
CERTIFICATO

Cap. Soc. € 1.891.776,93 int. vers. - C.F. 03636630372 - P. Iva 00644831208 R.E.A. 0305386/BO - Reg. Imprese 45539/BO - Mecc. BO 012048

UNI EN ISO 45001
Cert. N. 7838-l UNI EN ISO 14001
Cert. N. 7838-E

IATF 16049
Cert. N. 9136.0

Mod 3065 rev 05

Consolidated Net Financial Debt

(In thousands of euro) At 30 June 2025 At 31 December 2024
(A) Cash on hand 62,032 102,991
(B) Cash equivalents
(C Other current financial assets 1,846 30,985
(D) Cash and cash equivalents (A)+(B)+(C) 63,878 133,976
(E Current financial payables 15,866 30,804
(E Current portion of non-current payables 91,731 53,797
(G) Current financial debt (E) + (F) 107,597 84,601
(H) Net current financial debt (G) - (D) (43,719) 49,375
(1) Non-current financial payables 223,849 268,404
(J) Debt obligations
(K Commercial and other non-current debt 467 757
(L) Non-current financial debt (I) + (J) + (K) 224,316 269,161
(M) Total net financial debt (H)-(L) (268,035) (219,786)

Cuini EN ISO 9001

IT-25917-9190.GVS1

GVS S.p.A.

Via Roma, 50 - 40069 Zola Predosa (Bologna) - Italy Tel. +39 051 6176311 - Fax +39 051 6176200 - e-mail: [email protected] - www.gvs.com Cap. Soc. € 1.891.776,93 int. vers. - C.F. 03636630372 - P. Iva 00644831208 R.E.A. 0305386/BO - Reg. Imprese 45539/BO - Mecc. BO 012048

UNI EN ISO 14001
Cert. N. 7838-E

A DI GESTIC
RTIFICATO UNI EN ISO 45001
Cert. N. 7838-l